Engels, F.K.

docetaxel patient cancer ketoconazole cyp 3a study pharmacokinetic treatment cannabi clearance variability excretion parent drug excretion sample interindividual variability polysorbate plasma formulation verweij j docetaxel clearance parent cyp 3a activity exposure administration toxicity activity value concentration phase trial effect analysis dosing interindividual course radioactivity polysorbate 80 pharmacol urine method oncol chapter metabolism microdialysi tumor table verweij metastatic breast cancer infusion parent drug cancer patients parameter faecal presence range result anticancer recovery development efficacy faece tumour cytochrome allele ratio taxotere tissue irinotecan strategy breast agent metabolite group difference fl ow rate sparreboom metastatic schedule inhibition cyp 3a allele